Treatment Retention

Harvie Says Use the Data!

When treating patients with opioid use disorder, treatment retention is everything. When patients leave treatment, their risk of death increases sharply.

Multiple studies show that two medications – buprenorphine and methadone – reduce the risk of overdose death. Most studies have found a reduction of at least two-fold in overdose death rates, though some found even higher reductions. [1, 2, 3]

For any other disease, if a medication was proven to reduce the risk of death (of death, mind you, not just risk of disease complications), it would be malpractice not to prescribe the medication immediately for patients with the disease.

But for opioid use disorder, abstinence-based treatment providers neglect to use these life-saving medications for thousands of patients every day. Or they recommend extended-release naltrexone, marketed under its brand name Vivitrol, instead of buprenorphine or methadone. Though Vivitrol is FDA-approved to treat opioid use disorder, studies have not shown this medication reduces overdose deaths. In fact, there’s now some questions about uncounted overdose deaths of patients given Vivitrol in one of the big studies, the XBOT study. (https://www.scientificamerican.com/article/vivitrol-used-to-fight-opioid-misuse-has-a-major-overdose-problem/ )

But I digress, and that could be a blog for a whole other day. Back to treatment retention.

Researchers have been looking for factors that will retain patients in treatment with buprenorphine and methadone, once they are on these medications. A recent metanalysis found that contingency management didn’t help retention, and neither did integration of psychiatric and medical services. Interestingly, extended-release formulations of buprenorphine didn’t show longer treatment retention than daily dosing of medication. [4]

In a recent study in the Journal of the American Medical Association, by Noysk et al., methadone was associated with longer treatment retention than buprenorphine. [5]

This was a big study, involving over thirty thousand patients. It was done in British Columbia, Canada, from 2010 through 2020, and involved patients starting medication for opioid use disorder. Patients were excluded if they were younger than 18, pregnant, or incarcerated. Around 40% started buprenorphine. Males accounted for 66% of these patients, and the median age was 33 years old.

 The study authors found that patients who started buprenorphine/naloxone were significantly more likely to discontinue treatment compared to patients who started methadone. For the buprenorphine/naloxone patients, 88% had discontinued at 24 months, compared to 81.5% of patients who started methadone.

That translates into a 37 to 41 percent reduction in treatment discontinuation for methadone patients compared to buprenorphine patients.

There was no difference in mortality in the two groups of patients during treatment, however.

Importantly, the data collected during the study covered the years when fentanyl entered the drug supply of British Columbia. By 2016, fentanyl became the primary drug seen in opioid overdoses there.

But there are other reasons why this study may not be comparable in the U.S. For example, our U.S. system of specialized opioid treatment programs is different than treatment in Canada. While in the U.S., only treatment with buprenorphine products can be delivered in an office-based setting, Canada allow both methadone and buprenorphine to be provided in office settings. It seems probable that better retention would be seen in office-based settings.

The point of the study was that treatment retention was lower with buprenorphine compared to methadone. We’ve seen similar results in other studies.

Why is this data a big deal, you may ask. After all, U.S. guidelines don’t endorse buprenorphine over methadone. But some Canadian guidelines do. They say that buprenorphine/naloxone should be a first line agent, because it is safer than methadone. This study calls these guidelines into question.

Even though our U.S. guidelines don’t officially say buprenorphine is better than methadone, I see a bias against methadone even in Addiction Medicine circles. I’ve gone to state conferences where the speakers talk of the importance of starting patients on medication, and they talk for an hour about buprenorphine without once mentioning methadone.

I get it. Buprenorphine is much safer. It’s hard to inadvertently overdose a patient with buprenorphine.

But particularly in this time of fentanyl, we must consider the benefits of methadone. Methadone does not cause precipitated withdrawal in patients using fentanyl, which is a big advantage over buprenorphine. Sometimes we don’t get a second chance with these patients, if we start buprenorphine too soon and cause precipitated withdrawal. These days, we must consider either low-dose or high-dose induction strategies to start patients on buprenorphine.

Or we can avoid the issue altogether and start methadone.

To be fair, both methadone and buprenorphine show better retention in treatment with higher doses. For too long, treatment programs were too stingy with dosing for both, resulting in lower treatment retention.

When I first started working at an OTP in 2001, some physicians claimed that no patient needed more than 70mg. This was, literally, dead wrong. Studies showed doses of 80 to 120mg worked better and kept patients from relapsing and leaving treatment. Now, in these days of fentanyl as the main opioid of use, we often must use much higher doses of methadone to stabilize patients, into the high 100’s, 200’s, or more.

We saw the same trend in the 2010’s with buprenorphine doses, with some experts saying patients didn’t need over 16mg per day. Incredibly, several states (Tennessee and Virginia) passed legislation limiting patient doses to 16mg per day. Now we have study data showing that doses of 24mg and higher are associated with better treatment retention.

Studies of treatment retention could be confounded if adequate doses weren’t used.

Predictably, lower cost shows better retention in treatment. I guess I don’t need to explain that one.

Stopping methadone suddenly may feel worse to patients than stopping buprenorphine suddenly. I hear patients’ descriptions of both, and they seem to describe far worse withdrawal symptoms from methadone. Also, I suspect but cannot prove that it is easier to buy buprenorphine products on the street than it is to buy methadone. If a patient decides they want to leave treatment, for whatever reason, it may be easier to do if the patient is dosing on buprenorphine rather than methadone.

During the height of COVID, we saw better treatment retention with increased take homes. That was the reason SAMHSA changed the required time in treatment, to allow take home doses much more quickly. Not all OTPs are taking advantage of this loosening of take-home dose requirements. As I’ve blogged about in the past, medical providers should be looking closely at patients for earlier take homes.

I suspect there are factors we can’t easily quantify which influence treatment retention, like the atmosphere of the treatment program. Friendly, smiling faces are more likely to make patients feel welcome. Patients who feel accurate empathy from OTP staff – at all levels – are more likely to continue treatment. Patients who form good relationships with their counselors and medical providers are more likely to remain engaged in treatment.

Many of these factors can be changed with little effort and can have profound impact on treatment retention and survival. And maybe it’s time to recommend methadone with more vigor.

  1. Scholl et al., Drug and opioid-involved overdose deaths—United States, 2013–2017. MMWR Morb Mortal Wkly Rep 2019; 67 (5152):1419
  2. Sordo et al., “Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies, British Medical Journal,” 2017;357:1550
  3. Santo et al., “Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence,” JAMA Psychiatry, 2021 June 2;78(9):1-15.
  4. Chan et al., “Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review,” Journal of Addiction Medicine, 2020 Sep 17;15(1):74–84.
  5. JAMA. 2024;332(21):1822-1831. doi:10.1001/jama.2024.16954
  6. Klimas, J., Hamilton, MA., Gorfinkel, L. et al. Retention in opioid agonist treatment: a rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev 10, 216 (2021). https://doi.org/10.1186/s13643-021-01764-9

Drug Screens and Blue Hair

“I feel like when you look at me, all you see are my drug screens.” This was said to me by one of my patients, when I was meeting with her to discuss her benzodiazepine-positive drug screen.

My reflex was to deny she was correct. But her words stuck in my mind and I came to see she was right. Every time I saw her, walking around the opioid treatment program, I worried she would have an overdose from the combination of illicit benzodiazepines and the methadone I was prescribing. When I met her in the lobby, coming or going, I felt worry. I always greeted her, but I’m guessing she could see disapproval and worry on my face.

I do not have a good poker face.

But she had hit on something deeper and more profound. I had been interacting with her on a superficial level, worried about problem drug use but missing the bigger picture. For example, she is a talented artist. She is an excellent mother. She is generous, often helping other patients with rides to the opioid treatment program. And she struggles with mental health issues, which are likely fueling her benzodiazepine use.

She is so much more than the illicit drugs she happens to be using at any time.

The other day she had blue hair. Not that bright blue awful-looking color, but a deep blue that blended nicely with her dark hair. I was fascinated and asked all about it: where did she get it done (did it herself), how permanent was it (lasts for a few weeks) and how hard was it to do (not at all difficult). I doubt I will be sporting blue hair anytime soon but maybe in my older age…

I hope I’m not deluding myself, but I think she helped me look deeper at patients. I can’t ignore my patients’ use disorder issues, because that is my job. But I can take time to think about who they are as a total person. Maybe I can see a bigger picture and do a better job of helping them achieve their goals.

My patients continue to teach me, when I can be open to learning.  

Book Review: “Motivational Interviewing: Helping People Change and Grow,” by William Miller and Stephen Rollnick, Fourth Edition

I just finished this book and it’s the best of their four editions. This one has less jargon and is more accessible and understandable. This edition also has long strings of dialogue between helper and patient (or client, help-ee, service recipient, customer, or your term of choice). I find these dialogue examples valuable.

What is Motivational Interviewing? Combining several definitions, it’s a collaborative method of counseling that pays particular attention to the language of change. This collaborative method seeks to elicit the counseled person’s own reasons for change and explore that in a compassionate and respectful manner.

Motivational Interviewing (MI) has been used successfully in many settings: psychotherapy, healthcare, substance use disorder counseling, nutritional counseling, coaching, social work, pastoral counseling…indeed any profession where one person seeks to help another person change and grow.

The authors say the spirit of MI is the key to its success. The helper (or counselor, therapist, medical practitioner) needs to have a collaborative attitude and exhibit genuine compassion and acceptance of the patient (person being helped). The helper respects the patient’s ability to uncover unique solutions to problematic behaviors. This attitude, or spirit of MI, is what keeps it from becoming a manipulative technique to use on people to trick them into change. MI does not seek to change people in ways they do not want. MI is a technique used with the patient, not to the patient.

After the introductory chapters of the book, subsequent chapters explain the actual method of MI. The authors describe the four tasks of MI: engaging, focusing, evoking, and planning.

Engaging with the patient includes establishing a trusting relationship. Naturally, humans don’t tend to be open with people they don’t trust. Being friendly helps but isn’t sufficient for a working alliance. The patient needs to feel acceptance and respect from an attentive, non-judgmental and compassionate helper. Indeed, in studies of patients with substance use disorders, one key indicator of success in the counseling relationship is a trusting working alliance.

The next task is focusing, or deciding what issue is going to be addressed in the counseling relationship. As the authors point out, the nature of the setting may imply the problem that is to be focused on. For example, I work at an opioid treatment program. Implied in the very presence of a new patient is that she or he is seeking help with opioid use disorder. At a domestic violence shelter, the focus would be much different.

In a more general counseling setting, discussions between the counselor and client should outline what topics the client wants to address. Often, these can change over time.

Next is evoking. This is MI’s term for eliciting change talk. In other words, the helper tries to get the patient to explain why change is needed concerning a certain behavior. This is called “change talk.” Because ambivalence about prospective change is nearly universal, this kind of talk is distinguished from “sustain talk,” which is about why change is not desirable, or why it is too difficult.

Careful listening is key to all stages of Motivational Interviewing. MI involves reflective listening and summarizing what the patient is saying, to check accurate understanding.

MI itself has changed and grown, as described in the preface of this book. The authors have changed some of their terms to be more in keeping with the spirit of MI. For example, in previous editions of this book, the authors talked about “rolling with the resistance” exhibited by the patient. In this edition, the authors describe resistance as a normal client response in the change process. The authors point out that what was called resistance can be the client’s response to the counselor’s words. In this version of MI, the authors discarded the idea of resistance in favor of the term “sustain talk,” which is verbalizations in favor of the status quo and against change.

Part of the helper’s role is seen as trying to evoke change talk, and to soften sustain talk. Here’s a sentence from Chapter 14, “Responding to Sustain Talk and Discord,” that really resonated with me: “Viewing sustain talk or discord as a character flaw is a sad mistake, for they lie at the very heart of human change.” Ambivalence is completely normal and a necessary prelude to change.

Amen. This statement seems to sum up how humans change. It can be a messy business, with lots of in-between situations where we want to change, maybe…but maybe not. Motivational interviewing honors these situations as an expected part of the change process. People gradually evaluate the pros and cons of change. Part of them wants to change and part of them does not. This is true for all kinds of human behavior, not just for drug use.  Anyone trying to break a destructive habit knows how hard it can be. Stopping drug use, which is strongly rewarding to the brain, is arguably even more difficult.

With Motivational Interviewing, the counselor can help the client identify what they want to change and how to do it, which brings in the last of the four chores of MI: planning.

Planning is tackled after the patient decides what they want to change and why. The “how” of change is discussed when the patient is ready for action. The authors say that patients start talking more about change and less about the desirability of the status quo when they reach the planning stage.

In this phase, the helper can support self-efficacy of the patient. That is, the helper can encourage the patient that change is possible. The helper can remind the patient of her strengths and how she has succeeded in other difficult situations.

Since most of us change a little at a time, it may not be practical to expect a success-only change process. In fact, sometimes the patient may lose the desire for change, and may go back to previous stages of engaging, focusing, and evoking.

Confrontation is not an MI principle. In days of yore, the substance use disorder counseling field thought patients must be confronted harshly to “break through” to them, to crush their resistance to change. We now know this can harm patients. This heavy-handed approach can anger patients, who feel – accurately – like their feelings and beliefs and life experiences are not being respected.

Sometimes when confronted harshly, patients become superficially compliant and agreeable. They say what their counselor wants to hear, and there’s no genuine helping relationship. In other cases, patients leave care, often feeling more discouraged about change.

The authors included a chapter on the importance of learning how to get better at Motivational Interviewing. To improve MI skills, listening to actual sessions with patients and getting feedback from others is essential. Of course, recordings of sessions must be done only with permission from the patient, but is one of the best ways to get feedback on one’s proficiency at MI. There are scoring techniques and methods that measure adherence to MI principles.

My husband has done quite a bit of training in MI, to the point he is now a MINT (Motivational Interviewing Network of Trainers) trainer. This means he teaches MI to other people, besides using it daily with his own patients (clients).

When he provided clinical supervision for the counselors at an opioid treatment program where we both worked, the counselors, with patient permission, made recordings of sessions to review themselves and for him to review so they got feedback on how to improve their skills.

Of course I am biased, but during that time I felt like patient and staff morale was at its peak. I think using MI at the OTP helped the counselors relax, because it took pressure off them. They were not responsible for making anyone do – or not do – anything. They had a counseling technique that helped them listen to the patient, elicit change talk, and help the patient plan the changes the patients desired.

The patients were more relaxed because they felt their counselors genuinely cared about and respected them. Patients felt their input and ideas were listened to, and they felt supported when attempting change.

Later, when the OTP managers decided to revert to traditional clinical supervision, I felt like morale slumped again, and counselor tension increased. Of course, I realize I’m biased in favor of my husband. My perceptions may not be accurate.

The authors of this book mention that using MI cuts down on counselor (or practitioner) burnout, because it’s a more relaxing method of counseling.

I am a relative amateur at MI. I’ve taken one- or two-day seminars about MI about three times over the years and attended many one -or two- hour training sessions about the basics of MI. As I said above, I’ve read books about MI, and I’ve watched MI sessions on YouTube.

If you’d like to watch examples of MI sessions, go to YouTube and search for “motivational interviewing” and you’ll find all kinds of examples. I’ve learned a lot from watching Dr. William Miller’s sessions and others. When a practitioner is very good at MI, it looks so easy. But it is not, at least for me.

I feel like I’m naturally good at reflecting the content and the feeling of what my patients say. We had courses on reflective listening in medical school, which helped. I usually feel genuine compassion, and I love a good double-sided reflection (“On the one hand, you enjoy the energy that cocaine gives you, and on the other hand you hate the jittery feelings that you sometimes get.”).

I tend to falter when we get to the planning stage. I revert to advice-giving too easily. In earlier editions of this book, this was called the “righting reflex.” In this edition it is called the “fixing reflex.” Most helpers have a deep need to fix things for people. If only we could say the right words and give the right advice and the patient would just listen to us, all would be well.

But people rarely hear good advice, then change forever. That’s not how most humans change, and our good intentions can push people away.

After reading this book, I understand that though I can perhaps guide a patient to a problem’s solution, the answer comes from the patient. Patients know their situation better than anyone. One of the principles of MI is that each person knows what solution will work for them. Instead of the helper (me) giving advice, the spirit of MI says it’s better if I elicit possible solutions from the patient. Each patient is the expert on himself or herself.

One of the final chapters discusses the efficacy of MI. The authors say more than 2000 studies of MI show that overall, patients have outcomes with statistically significant improvement with MI compared to doing nothing or with telling patients what to do. This is indeed an evidence-based method of counseling.

This interesting book describes the spirit and practice of the Motivational Interviewing style of counseling. Reading it won’t make you an expert, but it’s a great starting point for learning how you can help people change and grow. I highly recommend it for anyone working in the helping professions.

Controversy Over Opioid Overdose Medications

This is the spoon sculpture by Fernando Alvarez, placed in front of Purdue Pharma’s offices in 2018

Currently there’s controversy about which medication is best to reverse opioid overdose.

For many years, naloxone has been our go-to medication. It can be used in intravenous (IV), intramuscular (IM), intranasal (IN), and subcutaneous (SC) forms. One of the brand names for naloxone is well-known: Narcan.

Now there’s several high-dose forms of nasal naloxone on the market: Kloxxado is the brand name of a nasal spray naloxone dosed at 8mg, twice the standard dose of 4mg for other naloxone nasal spray products. One carton of this medication contains two doses of 8mg, and according to Goodrx.com, with a coupon it costs $142. Then there’s Rezenopy, a nasal spray of naloxone of 10mg per dose, approved earlier this year. I couldn’t find a price for this last medication.

Harm reduction advocates worry that high-dose naloxone will cause more side effects from severe precipitated opioid withdrawal. They promote a lower-dose version of naloxone spray, such as the brand RiVive, which contains 3mg per dose. A carton with two vials costs $42, only 30% of the high dose form.

As an alternative, harm reduction advocates recommend continued use of naloxone IV or IM, dosed in .4mg increments, as we have been doing for years, titrating the dose until the patient is breathing again. The cost of a box of two vials of generic naloxone containing .4mg each is $14. Of course, the medication must be drawn up into a syringe and injected into muscle or vein or subcutaneous tissue, making administration a little more complicated than the nasal spray.

Most opioid overdoses are now caused by fentanyl and its analogues, which are more potent. Some people – and drug manufacturers – believe higher doses of naloxone are warranted. Pharmaceutical companies have revived (pun intended) an older opioid antagonist, nalmefene.

Nalmefene is an opioid antagonist that was originally approved for opioid overdose reversal in 1995, but it was removed from the market in 2008 for commercial reasons. I assume this means the drug company didn’t make any money from it. The brand name was Revex and it could be used intravenously (IV), intramuscularly (IM), and subcutaneously (SC).

Nalmefene has a higher affinity for opioid receptor than naloxone and longer duration of action, lasting around seven hours compared to one or two hours for naloxone. This means it can cause precipitated opioid withdrawal which is more severe and longer lasting.

In May of 2023, the FDA approved nalmefene in the form of nasal spray as an emergency treatment for opioid overdose. One brand name is Opvee, a nasal spray containing 2.7mg per dose with two nasal sprays per carton, marketed by Indivior. According to Goodrx.com, with a coupon, the price is $116, for one carton. This compares to nasal generic naloxone, which contains 2 doses of 4mg each, at $47 per carton.

Another brand of nalmefene was just approved in August of 2024: Zurnai. It is an autoinjector which delivers 1.5mg of nalmefene either SC or IM. This drug is manufactured by Purdue Pharma and will be available in early 2025. There’s no mention of how much it will cost that I could find on the internet.

Yeah. I know what you’re thinking.

Didn’t Purdue Pharma declare bankruptcy? Didn’t they go out of business because of their criminal misbranding of OxyContin and so they could avoid being sued by people who were harmed by OxyContin?

It appears that Purdue Pharma, not unlike an apocalyptic zombie, has risen from the dead. They still face lawsuits but have not stopped making drugs.

In 2020, Purdue Pharma pled guilty to three felonies; one count of conspiracy to defraud the U.S and the Food, Drug, and Cosmetics Act, and two counts of conspiracy to violate anti-kickback laws. They were fined $3.5 billion and $2 billion for criminal forfeiture, for a grand total of $5.5 billion. Also, the company agreed to become a “public benefit company.”

This is a thing.

A public benefit company is still a for-profit business, but it is legally required to generate social and environmental good. It must consider the social impacts of its business activities, in addition to maximizing value to shareholders.

Should we trust this company to make profits in a way that benefits society at large?

I have so many questions. Are the same people in positions of authority at the drug company? Is the Sackler family still the only shareholders of this company? How is the company monitored for compliance with its new beneficial intent?

Because I would not trust the old Purdue Pharma. If the old Purdue Pharma as a company could morph into human form, and were walking toward me on the sidewalk, I would put my keys between my fingers and cross to the other side of the street.

But let’s get back to nalmefene.

Because this drug was already approved by the FDA for IV use back in the 1990’s, the intranasal use request didn’t require new data. In what’s called an “Abbreviated New Drug Application pathway, the manufacturer only needed to show the drug was pharmacokinetically equivalent to the injectable form. That was easily accomplished.

However, the original data from the mid-1990’s about nalmefene was based mostly on post op patients. In one study, only about one quarter of the 1,127 test subjects got the medication to reverse an opioid overdose.

The better question is how do the two antagonists, naloxone and nalmefene, compare as far as outcomes and side effects?

I found one small study of 176 patients that compared three treatments: 2mg of IV naloxone, 1mg of IV nalmefene, or 2mg of IV nalmefene. In that study, all three treatments were effective, with no difference in adverse effects. But as one commenter pointed out, this study was probably too small to see differences in adverse effects, even if they were present.

Then several days ago, just as I was researching for this blog, another study was released. Near the beginning of the article, the author says, “The increasing number of overdose deaths involving long-acting, potent synthetic opioids and increasing use of multiple opioids suggest the need for stronger, longer-acting opioid antagonist treatments.”

That introductory statement felt more like an opinion versus fact, but I read on. Right away, I saw the study was small and that it was done on healthy volunteers, not patients with opioid use disorder. I questioned whether the findings would relate to my patients.

The researchers’ conclusion statement of data says that intramuscular nalmefene at a dose of 1mg reversed respiratory depression induced by fentanyl “similar to or better than intramuscular and intranasal naloxone.”

Their study appeared in the Journal of Clinical Pharmacology: (https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.6132 ).

I have no reason to think this journal is anything other than a legitimate scientific publication.

However, at the end of this study, I read that four of the study’s authors work for a company that is a subsidiary of Purdue Pharma. I will leave readers to decide how much credibility to give this data.

But what about the study’s introductory statement? Is it true? Is a more potent and higher dose of an opioid antagonist better for reviving people with opioid overdose? Maybe not. What do we want to achieve with opioid antagonist treatment? Isn’t it to get the patient breathing again? Do we need to make the patient fully awake – and in misery from withdrawal?

In other words: what should a successful opioid overdose reversal look like?

Many prominent experts are asking for more data before switching from traditional naloxone doses or switching to nalmefene. They are concerned about side effects from high doses and longer-acting antagonists, and say we need more data from studies.

A group of experts from my state of North Carolina, including Addiction Medicine physicians, researchers with PhDs, frontline harm reduction workers, licensed counselors and therapists and people with lived experience composed a petition against implementing the use of higher dose, longer acting antagonists.

Their main points are that naloxone as we’ve been using has worked well. To get an overdose victim breathing again, on the average it takes only 1.6 doses. This indicates current medication is effective. The group also said that a patient thrown into severe and prolonged withdrawal after administration of a more powerful antagonist might well push that patient to leave the hospital to seek relief from re-administration of an illicit opioid.

This group agrees that this medication, nalmefene, has never been used on patients like the ones we are treating now in North Carolina. More testing seems prudent before use of this product, and there is no rush to make a switch, since naloxone in standard doses is working well.

Additionally, the American College of Medical Toxicology and the American Academy of Clinical Toxicology published a joint position statement about the use of the newer nalmefene versus traditional naloxone. Toxicologists are the experts in the field, so that carries weight with me.

Their position statement  (https://www.acmt.net/wp-content/uploads/2023/12/ACMT-AACT-Joint-PS_Nalmefene.pdf  ) gave data comparing  the properties of nalmefene and naloxone and reviewed our current state of information about the two medications for treating overdose. In their conclusions, they said, “We are concerned that use of a longer-acting reversal agent would not improve on current practice and could potentially cause harm.”

They also concluded that patients revived with nalmefene may need to be watched for longer in the emergency department because the half-life is so much longer.

I also heard this at the spring American Society of Addiction Medicine conference. Speakers at a session on this same topic, who worked in emergency departments, opined that if nalmefene was used for overdose, patients would need to be observed for around seven hours, to see if respiratory depression would recur. With naloxone, they usually keep patients an hour or two after opioid reversal, because of the much shorter half-life of naloxone.

The toxicologists go on to say we don’t have enough studies to risk using nalmefene when there is the possibility of unknown side effects, though they encourage these studies be done. They say naloxone should remain our primary opioid reversal product.

So it appears the experts are in agreement: they do not think it wise to switch opioid reversal agents until we have more data and unless newer agents and doses are proven safe.

I also wonder about the pricing of these new products. For sure, newer products cost more, as you can see from the price comparisons I gave above. Drug companies in this country made money off the opioid epidemic. I remain suspicious of higher-cost products to reverse opioid overdoses.

We really need input from people with lived experience. What do people who have been through an overdose reversal say? How different does it feel to be revived to the point of breathing spontaneously, compared to being put into full withdrawal for an extended time? I am assuming the latter would be much more difficult. I also assume a patient in more severe withdrawal would be more likely to leave the emergency department to seek relief from illicit opioids. But we need to hear from the people who know, and then we need to listen to them.

And for me at least, I’m going to need studies from researchers who are not on Purdue Pharma’s payroll. I just don’t trust this company.

The Corporate Practice of Medicine Doctrine

This blog might be tedious for many readers. It’s kind of a confusing topic, and I will try to make it as simple as possible while still relating information.

In North Carolina, as in many states, there’s a law called the “Corporate practice of medicine doctrine,” which I will abbreviate as CPOM. In broad terms, this law seeks to prevent non-physicians from owning medical practices. The law believes it’s in the public’s best interest if non-physicians are not allowed to employ physicians, because the non-physician bosses could unduly influence physicians’ judgments. In other words, the law doesn’t want non-physicians to make medical decisions.

The goal of this doctrine is to protect the public from commercial influence.

Our state says that all corporate entities that provide medical care must be 100% owned by a physician or physicians licensed to practice medicine in our state.

In fact, on our state medical board’s website, they posted information about the CPOM: https://www.ncmedboard.org/resources-information/professional-resources/laws-rules-position-statements/position-statements/print/corporate-practice-of-medicine

In the above reference, the medical board states that the physician who participated in allowing the CPOM is subject to discipline by the state’s medical board. This could range from a public letter of reprimand or a monetary fine up to an adverse action against the physician’s license.

By now some readers are saying “Wait a minute. Maybe back in the 1950’s this sort of law was appropriate and enforced with regularity. But now…most medical practices are owned by hospital corporations, which certainly aren’t owned by doctors.”

You’re right. Starting in the 1990’s, hospital corporations started buying up physician outpatient practices, and now own more than 50% nationwide.

But at least in North Carolina, the medical board does not consider hospital-owned practices to be in violation of the corporate practice of medicine laws because it assumes that hospitals have the public’s best interests at heart, just like the medical board does.

The NCMB also does not enforce the CPOM act if the agency hiring physicians is non-profit, feeling that non-profit companies, as opposed to for-profit, have the publics best interests at heart and do not interfere with the physicians’ judgements. They also do not enforce CPOM against Health Maintenance Organizations, or HMOs.

So why am I talking about the CPOM doctrine on a blog about opioid use disorder and its treatment with medications? It’s a curious story.

Years ago, treating people with opioid use disorder with medication meant getting treatment at an opioid treatment program that was heavily licensed, inspected, and regulated. It was cut out from traditional medical care. Only with the DATA 2000 law did that change, making it legal for appropriately licensed providers to prescribe buprenorphine products from their offices. But methadone treatment for opioid use disorder remained siloed from the rest of medicine, for the most part. There were exceptions but I’m trying to keep things simple.

Today, opioid treatment programs can have all sorts of corporate structures. Some are owned by one or more physicians which means they aren’t in conflict with the CPOM act.

However, it’s a big investment to open an OTP, so most OTPs are owned by organizations with deep pockets. There are a handful of corporations that own and operate many, perhaps a majority, of OTPs in the U.S. These are for-profit and, in some cases, owned by venture capital groups.

Do these OTPs violate the CPOM act? Many years ago, I tried to find out.

I was contemplating working for a for-profit organization that owns OTPs in several states. I wanted to know if I could be at risk of being charged by the state medical board for “aiding and abetting the Corporate Practice of Medicine.”

Around 2009, I called the NCMB and asked to speak to one of their lawyers. I can’t remember his name, but he was polite and a little scary, as if he thought I must be up to something to voluntarily call a board lawyer. But that could have all been my imagination.

I explained to him that I needed clarification about the NCMB’s enforcement of the CPOM. I told him I had worked for a non-profit OTP and knew that the NCMB didn’t apply the CPOM regulations against non-profit agencies, but that I was now due to start at a for-profit OTP, and wanted to make sure the NCMB had no problem with this.

The NCMB lawyer told me that if this OTP was for-profit, and not a hospital (it wasn’t, of course), if the NCMB found out about it and they investigated, I may have disciplinary action brought against me. I argued a little bit, saying that probably half the OTPs in the state were for-profit and surely he wouldn’t take action against all of them, since they provided essential and life-saving service. He said he would if it came to his attention.

He said I needed legal counsel before I started working for the second OTP.

Disappointed and heavy-hearted, I thanked him for his time and got off the phone, puzzled about what to do next. The idea of paying a lawyer to help me work this out was daunting, but I really loved working at OTPs.

I remembered the name of a lawyer who retired from working for the NCMB and now had a private practice specializing in helping physicians with legal problems, so I called him. Incredibly, he happened to answer his own phone that day.

I briefly explained the situation to him. As we talked, he reminded me that by law, OTPs must have a physician medical director, and he felt one law couldn’t prevent what another law commanded. He said it wasn’t up to me or any other private citizen to figure this out, and that the state’s division of Health and Human Services needed to get with the NCMB and come to an agreement about the status of OTPs and the CPOM law.

This sounded right to me, since I didn’t have the money to hire a fancy lawyer anyway.

Satisfied with this course of action, I took the OTP job.

I am not sure if the NCMB and NC DHHS ever got together to carve out an exception for OTPs and the CPOM. But after my phone call with these two lawyers, I felt I should probably stay out of the middle of that, because it wasn’t my problem to fix.

I’ve worked for six different OTP systems over the twenty-three years total that I’ve worked in Addiction Medicine. I’ve worked for non-profits, for-profits, physician-owned, and those owned by venture capitalists.

I feel many of the for-profit companies get undeserved criticisms. They aren’t all run the same; some are much better than others. Were it not for these large companies, we wouldn’t have enough treatment slots for patients needing help. The for-profit programs have undoubtedly saved many lives. They also tend to have deeper pockets and can withstand financial challenges.

Of course, the whole reason for the CPOM doctrine is, as described at the beginning of this blog, to prevent non-physician program owners from dictating healthcare for vulnerable patients. Non-physician people who own companies and make money off them could choose to put profits ahead of patient well-being.

Have I encountered the corporate practice of medicine at OTPs? Yes, unfortunately.

With one glaring exception, these non-physician attempts to control medical decisions weren’t committed by the owners or the heads of corporations, but rather by isolated middle-managers. I suspect they were motivated by the yearning for bonuses or by their desire to climb the corporate ladder.

I’ve responded to these unfortunate situations in different ways over the years. I found it best to talk to the manager involved, taking care to be nice and explain how what they are doing could harm patients. Much of the time, managers don’t have the medical knowledge and foresight that medical providers are trained to have. Calm conversations have big benefits. I’ve found some managers aren’t open to conversation, and that’s essential information for me as well.

If a mid-level manager is getting ready to crash and burn, I might wait a bit to see what happens. Managers come and go. Most of the ones I’ve worked with have been great, and a real support for me to turn to. The others…they usually move on. Sometimes they are promoted. Good for them, if they are no longer interfering with patient care.

I resigned from several jobs when the above techniques got me nowhere. If I really feel that my ability to care for patients is impaired, I can’t stay.

So what is the answer?

I’m not sure.

The idea of prohibiting the corporate practice of medicine is sound, but I fear our present system has already travelled too far down the road of corporatization of medicine. To turn the practice of medicine back over to medical providers might be too big a jump without scraping our entire system and starting over.

Book Review: “Fentanyl Nation: Toxic Politics and America’s Failed War on Drugs,” by Ryan Hampton

I really liked this author’s last book, “Unsettled,” about Purdue Pharma’s declaration of bankruptcy and attempt to settle scores of lawsuits, so I knew I’d probably like this book too.

I wasn’t wrong. Ryan started his book with the story of a policeman who supposedly overdosed while handling fentanyl belonging to a drug user he was arresting. As all of us should know by now, fentanyl does not penetrate the skin. The officer’s episode was due to his terror of fentanyl. His episode was caused by fear, not fentanyl. The author uses this incident as an example of the hysterical attitudes we have in the U.S.  towards drugs and their effects.

We don’t have a great record of adhering only to science when promulgating laws and policies to govern our nation. That’s one of the main points of the book.

The book describes the start of the War of Drugs, announced by Nixon in 1971, who said drugs were public enemy number one. As we know now, the War of Drugs was really the War on Some People Who Use Drugs, because that war was fought with more vigor against users who happened to be minorities. The author gives numerous examples of minorities who have been scapegoated over the years when politicians blamed their drug use as the cause of society’s many problems. The War on Drugs was used as an excuse to criticize, marginalize, and incarcerate people of color, sexual minorities, the poor, the mentally ill, and other groups.

Unlike the author, I can remember 1971.

I remember watching Nixon on TV, jowls shaking with judgment as he castigated drugs and the people who used them. After the news was over, my father lectured my sister and me about the evils of drug use. His admonition might have been more effective had he been sober, but he was what he called “pretty well lit” by that time in the evening. I’m sure it never crossed my father’s mind that the ten or so beers he consumed over several hours might be considered by some to be hazardous drug use. Of course, that drug was legal.

Even at ten years old, I wondered why some drugs were bad, but others were OK, especially since alcohol caused so much trouble in our household.

The book also describes positive things Nixon brought into place. For example, he appointed Dr Jerome Jaffe as leader of the forerunner agency to the ONDCP (Office of National Drug Control Policy). Dr. Jaffe was interested in helping patients with opioid use disorder and started a network of methadone treatment programs. Nixon eventually granted more money to demand reduction (treatment) than to supply reduction (law enforcement) but unfortunately that situation only lasted a few years.

I’m pleased the author explained how treatment with methadone is lifesaving and certainly one of the most evidence-based treatments in all medicine. However, I was offended at the author’s description of present-day opioid treatment programs. He calls them methadone clinics, though most dose patients with both methadone and buprenorphine. On page 51, he says, “Run down and depressing, methadone clinics are usually only found in poor communities of color.”

Over the past twenty-three years, I’ve worked at fourteen different clinic sites. Only two fit Ryan’s description. The other twelve were outfitted to look like the medical facilities that they were. Most were in rural or suburban areas, and most took great care to keep the facility tidy and cheerful. If we need to lose old prejudices, let’s lose the ones about “methadone clinics” too. We’ve come a long way.

Then the book described how during the Reagan years, harsh drug laws were passed, with mandatory minimum sentences, resulting in expansion of our prison population. Another chapter describes the dilemma of the low-level dealer/user who is caught by police and threatened with long prison sentences unless they give the name of the person they buy from. Harsh federal drug laws turn these people into pawns of the system, subject to decades in prison.

Even worse, many states have recently passed laws allowing charges of murder to be brought against a person who gives or sells a dose of fentanyl to someone who then dies of an overdose. The author gives several examples of people who got long prison sentences under this law, even though they were users of heroin as well, and just as much in need of treatment and help as the deceased.

It’s obvious author Ryan Hampton knows his facts and has spoken to many experts about our present-day situation. He’s also done research on solutions. In Chapter 6, titled “In search of a new model,” the author talks about the successes seen in Portugal after they decided to institute programs designed to treat drug use as the medical problem that it is, rather than as a crime.

In 2001, Portugal decriminalized drug use. They did not legalize drugs, but rather removed criminal penalties for possessing drugs for personal use. But that was just the start: their new policy was rooted in harm reduction, making resources easily available for people who wanted help drug use. They made sure that help was compassionate and nonpunitive, without stigmatization, and available when requested.

As a result, the author says Portugal’s drug related deaths have remained lower than the EU average, the proportion of prisoners incarcerated for drugs dropped from 40 percent to 15 percent, and rates of drug use in Portugal has remained below the average for the rest of Europe.

Sadly, things unraveled in Portugal after the funding for these policies was cut drastically.

I listened to a lecture last spring at the national Addiction Medicine conference by Dr. Carl Erik Fisher (author of the erudite book “The Urge”), who summarized the successes in Portugal, then what happened when the funding was cut. As expected, when successful programs lose their funding, they don’t work as well.

But the U.S. just got literal billions of dollars from opioid distributors and manufacturers of prescription opioid, so we have more funding available for programs proven to be effective. Will these billions be spent on programs that are evidence-based, or on the same old attempts at supply reduction that have failed for years?

The author describes the Rand Corp’s report from 2023 titled “America’s Opioid Ecosystem: How Leveraging System Interactions Can Help Curb Addiction, Overdose, and Other Harms.” In brief, their main points included that supply control and reduction is not effective. Arresting dealers at the street level rarely means the drug supply dries up or that prices increase, which are both factors that make drug use less attractive to users. Extremely potent fentanyl is very cheap, relative to the heroin of yore. Drug raids that result in the arrest of local dealers sometimes disrupts the drug supply. New sources of fentanyl often cause increases in overdoses, due to changes in the drug’s purity.

Further in the book he explains how precursor chemicals get shipped from China or India to countries in South or North America, to be made into fentanyl. He says the supply of fentanyl, so easy to make with little labor compared to old-fashioned heroin, it endless. If the DEA or other authorities do intercept some of the fentanyl there’s much, much more being shipped, and the supply won’t be interrupted. As he puts it: “The supply is bottomless.”

The last chapter, titled “Blazing a New Path,” is the best. In this chapter, Ryan outlines the problems with our past approach to substance use in the U.S., largely one of crime and punishment for people who use drugs. More spending has been focused on drug eradication, which is not realistic. Despite seizures of large amounts of fentanyl at the border, this author points out that fentanyl is cheaper than ever and easy to find.

What we are doing isn’t working.

Instead, Ryan Hampton has specific recommendations.

He advocates free naloxone for everyone. That’s common sense that I can agree with. In North Carolina and many other states, naloxone kits are over-the-counter, meaning people do not need a prescription. But if they were free of charge, that would be better. Ryan argues that naloxone, an old drug, is a cheap medication, or should be, until drug companies jacked up the price. Our government could make this happen.

He calls for real-time data about drug overdoses, and drug-related emergency department visits and hospitalizations. He also says that information about how many people are seeking treatment would be helpful. With our present system, we get essential data months later. What he’s saying makes sense, but I don’t know enough about data systems to know what the obstacles are to more timely data.

He recommends treatment on demand. This means when a person asks for help, they should be able to get it, and right away. Of course this is the ideal. I’m pleased to say that the opioid treatment programs I’ve worked for recently have provided something pretty close to this ideal; they offered same-day admission every weekday, or nearly every weekday, either in -person or with telehealth on day one.

People die on waiting lists. There should be no waiting lists, or only in rare instances from unusual circumstances. Every medical facility should know where to take or refer patients for immediate help when they ask for it.

The author wants treatment innovations. He says that though the NIH (National Institutes of Health) has a budget of over $40 billion, NIDA (National Institute on Drug Abuse) gets only around $1.5 billion.

He wants expanded recovery community organizations. He mentions 12-step recovery as an example of such a community but admits one organization won’t fit everyone. There’s no limit to the types of recovery groups that could be organized.

I know the non-profit recovery community organization in my area, Wilkes Recovery Revolution, has been recognized for its excellent work. I’ve talked to many people who have been helped by their many programs. They now have peer support services, a community center with computers available for use, and employment assistance. They have housing support as well as halfway houses for men and women. They are supportive to patients on MOUD. They offer harm reduction services like syringe exchange and free naloxone kits. They have been key resources for patients with substance use disorders and their families. These grass roots organizations are invaluable resources. Early on, Project Lazarus was the first non-profit organization in our county to provide assistance with naloxone kits, information and support to clinicians and agencies. Their main focus was overdose prevention but now they also assist in many other ways.

Ryan calls for housing first. He says providing housing to homeless people is the best way to lower overdose deaths rates and enable people to get healthcare.

He’s right about the changes needed in the U.S. substance use disorder treatment system. Of course, the entire U.S. healthcare system is broken, and in need of redesign. We spend more money on healthcare for a worse outcome than most high-income countries, with higher rates of avoidable deaths.

This is a great book packed with evidence-based ideas. Anyone who is interested in improving the care of patients with substance use disorders should read this book for some insight on methods that have been proven to work, as well as some that have been proven not to work.

We can learn from history – our own and from other countries. We do not need to keep making the same policy mistakes over and over.

Hepatitis Education Online

Last month I had a sudden change in my employment, giving me more free time. I’ve spent a great deal of that time catching up on continuing medical education hours, including how to treat uncomplicated Hepatitis C.

I have never worked at an opioid treatment program (OTP) where I could treat Hepatitis C. In the past, it felt too complicated, and OTP patients needing Hep C evaluation and treatment were referred to other providers. But newer guidelines have encouraged primary care providers to treat uncomplicated cases of Hepatitis C. This may allow more time for hepatologists (liver specialists) to treat the more complicated cases.

It makes sense for providers (physicians, nurse practitioners, physician assistants) who work at opioid treatment programs to treat patients with uncomplicated Hep C. We see these patients regularly, already have rapport with them (hopefully!), and already know their health histories.

This assumes OTPs have some means of screening for Hep C, and I think most do. In my area, harm reduction agencies work with the OTPs to provide some screening. In the past that meant doing antibody testing, but more recently they can test for Hep C RNA, looking for active infection.

That’s as far as care for Hep C went, but the treatment has gotten much easier in past years.

I searched the internet for an online course so I could learn more and found a great one:

https://www.hepatitisc.uw.edu/

For providers reading my blog, if you are interested in learning more about Hep C, even if you don’t intend to provide treatment, you need to take this course. It is comprehensive and informative, funded by the Centers for Disease Control and written by the University of Washington Infectious Diseases Education and Assessment Program. The CME credit, up to 31 hours is free, and provided by the University of Alabama. And yes…I said free CME.

I took the whole course, which took around thirty hours. Like I said…I had some free time. But for busy providers, it’s organized by short lessons on a topic, and very easy to stop and start. You can read the lesson, take the quiz, and come back for more information later. You can skip around, if you only want information about certain topics.

It’s ideal for the busy professional.

There are six modules: Screening and Diagnosis of Hepatitis C Infection; Evaluation, Staging, and Monitoring of Chronic Hepatitis C; Management of Cirrhosis-Related Complications; Evaluation and Preparation for Hepatitis C Treatment; Treatment of Hepatitis C; and Treatment of Key Populations and Unique Situations.

I already knew much of the material about screening and diagnosis, and while I appreciated the information in the module about treating cirrhosis-related complications, those are patients I would refer to hepatologists. The module about the evaluation and preparation for treatment was particularly helpful, emphasizing the need to get these patients vaccinated for other viral hepatitis types and screening for problems which may complicate treatment, like Hep B or HIV or the presence of uncompensated cirrhosis.

The website also has some handy tools, like charts of name brand treatment medications listing the generic components. The generic medication names are easy to confuse.

I already knew that current recommendations said ongoing intravenous drug use should not be an obstacle for patients seeking Hep C treatment. This module explained why: these are the patients most likely to transmit Hep C and cause new cases. In other words, these patients should be a priority, not made to wait until they’re done using drugs. Their response to treatment is just as good as non-using patients. There is a concern for re-infection for Hep C, but rates are surprisingly low.

I haven’t worked in primary care for over twenty years, but after studying this material, I feel confident I could treat patients with uncomplicated Hep C. The hardest part may be getting insurance companies to pay for treatment, but this online training says it is much easier, and most insurance companies have dropped prior authorization demands. Most have also dropped requirements that say Hep C must be causing damage before they will pay for treatment. After all, we can prevent this damage so why would we wait?

If you are a primary care provider, a treatment provider for an opioid treatment program, or have an office-based practice treating patients with substance use disorders, you should take this course and consider treating these patients. Treating patients before they get complications from Hep C saves a lot of expense and suffering, and the newer treatments are usually well-tolerated and very effective.

Again, here is the website: https://www.hepatitisc.uw.edu/go/screening-diagnosis/diagnostic-testing/core-concept/all

Long Blogging Break

Hello all!

As you may have noticed, I haven’t posted a blog entry recently. This is because I’m going to take a prolonged break. I started this blog in April, 2010, and haven’t missed a month since then. I’m tiring, and feel like I’m saying the same things over and over in my blog entries.

So I’m taking time off to re-charge.

Check back later….

Recommended Books Written by Dr. William Miller

I’m a big fan of Dr. William Miller. He wrote “Motivational Interviewing: Helping People Change and Grow,” with Stephen Rollnick. This was the foundational textbook about Motivational Interviewing technique of counseling. I’ve read the first three editions of the book and have the fourth edition but haven’t read it yet.

I also read “Rethinking Substance Use: What the Science Shows, and What We Should Do About It,” that he edited with Kathleen Carroll. That book was published in 2006, near the beginning of my career in Addiction Medicine, and I learned a great deal from it.

Then I read “Quantum Change: When Epiphanies and Sudden Insights Transform Ordinary Lives,” by Dr. Miller which was published in 2011. This book is completely different. It was so fascinating that I’ve re-read several times.

Dr. Miller’s books have been about how people change, and how counselors, therapists, and doctors can help them change. One of the main themes of his writings has been that change is a process and that most of us change gradually. The “Quantum Change” book describes the opposite: life experiences of people who had sudden changes in their personalities or behavior.

To find these people and get their case histories, he placed an advertisement in his city’s newspaper, asking people who had experienced such a change to contact him. Eighty-some people contacted him and of them, fifty-five were willing to meet and tell their stories.

In the “Quantum Change” book, Dr. Miller transcribed their interviews, then looked for what these unusual people had in common and what they didn’t.

He noted that people who had such experiences were ordinary, and usually were not seeking any sort of sudden change. They weren’t spectacularly high achieving or high net worth people. They were not spiritual gurus and mostly were surprised by their experiences.

About half of these people had sudden and intense feelings of transcendence outside of space and time. Many had a sense of being in the presence of some Other or Higher Power or God, depending on whether they were religious or not. These people struggled to put their experience into words.

Most of all, they didn’t feel afraid, and tended to feel deeply loved and accepted during their experience. Many of these people interpreted their experience as spiritual in nature, with reference to God or at least a Higher Power, but this wasn’t universal.

Dr. Miller said these people, whom he called quantum changers, shared a new knowledge of a power greater than themselves that was loving and accepting at a deep level. Some of them felt that lovingkindness was the essential nature of human experience.

 Intrigued by his findings, Dr. Miller explored lovingkindness as the topic of an entire book, titled “Lovingkindness: Realizing and Practicing Your True Self.” Published in 2017, it’s a short paperback, only eighty-two pages.

 I found it to be dense and interesting reading. It’s the kind of book I needed to sit and think about as I read it, coming back to some passages multiple times.

This book scratched me where I itched. I’ve been wrestling with being consistently compassionate, particularly with my patients, but not limited to them. I see consistent lovingkindness as a desirable way to live but wasn’t sure why I felt that way and wasn’t sure how to do it anyway. After a great deal of thought, I decided my interest in becoming a kinder and more loving person came in part from my desire to help people to change, and from feeling better about myself when I am loving and kind towards other people.

Dr. Miller, in the preface to his Lovingkindness book, said that all major religions called humans to practice compassion, or lovingkindness, in our daily lives.

In his book he describes how people must choose to want to become loving and kind, and must act, with selfless, consistent empathy. He says there are aspects of character which the person with lovingkindness must choose to embrace, such as forgiveness, contentment, gratefulness, and others.

He also outlines common blockades to lovingkindness and ideas to navigate around them. I found these chapters particularly helpful. These blockades can range from lack of mindfulness to holding on to fear and anger.

Dr Miller elaborates on the aspects of character necessary to cultivate lovingkindness in later chapters.

I went back and looked for other books by Dr. Miller and found “Living as If: How Positive Faith Can Change Your Life,” published in 2020. It’s also a short book of one hundred and twenty-seven pages.

While I read the “Living as If” book, I got deeper insight into my tendency towards negative thinking and how that pattern may have limited me over the years. I am by nature a sarcastic – but funny – pessimist. I’m often afraid to hope for the best from people, in order not to be hurt by them. Over the years I’ve tried to be more positive, only so I won’t be a wet blanket for my loved ones. After reading this little book, I recognized how negative thoughts often rob me of joy, and maybe keep me stuck in unnecessary fear.

Thanks to these books, I got a little more insight and more ideas to change my own long-standing behavioral patterns for a better life.

I highly recommend all of Dr. Miller’s books.

Possible New Illicit Drug

News outlets are describing a new illicit drug being sold on the street, often with fentanyl, named medetomidine, and its mirror-image molecule, dexmedetomidine, or “dex.”

Medetomidine is a synthetic medication that is an alpha-2-adrenergic agonist, meaning the medication stimulates the alpha-2-adrenergic receptors found in the brain. This produces effects of anesthesia, analgesia, and sedation. One form of medetomidine, called dexmedetomidine, is used in pediatric and adult medicine in the U.S. under the brand name Precedex. Medetomidine is also used in veterinary medicine.

Precedex is often used around the time of surgeries or medical procedures, to sedate patients. Product information from the drug company that makes Precedex says the medication can cause low blood pressure and slow heart rate, along with sedation, and recommends a patient receiving this medication have continuous monitoring of heart rate, blood pressure, and oxygen level. This information warns that opioids can intensify the sedation from dexmedetomidine.

Atipamezole is a medication that works as an antagonist at the alpha-2 receptors and is used to reverse the sedating effects of dexmedetomidine. It is unknown if this medication would serve as an antidote for overdoses of medetomidine and fentanyl or other opioids. Narcan does not reverse the effect of dexmedetomidine, because it has no action at any of the opioid receptor types.

Xylazine is also an alpha-2-adrenergic receptor agonist, but medetomidine is much more potent than xylazine. Xylazine has been found already in the nation’s illicit drug supply and is frequently found in drugs sold as fentanyl.

In the past I’ve been appalled by traditional news reports of new drug threats. Often, they exaggerate how severe or widespread the threat is. Non-scientific news outlets use lurid descriptions of the effects of new drugs. Does anyone remember descriptions of users of synthetic cathinones, also known as bath salts, or “flacca”? Eight or so years ago, reports blamed the drug for causing a user in Florida to eat the faces of several people, calling it the “cannibal” drug. Xylazine, also an alpha-2-adrenergic agonist, has been called the “zombie” drug. So has desomorphine, also known as Krokadil, which seemed to have been mostly limited to Russia, despite frightening reports from news outlets in the U.S.

We don’t need exaggerated or lurid claims about any drug of use. This dilutes credibility at a time when we need accurate data to help keep people alive.

To get the best and most up-to-date information for my state of North Carolina, I contacted UNC’s Street Drug Analysis Lab. Their website is: https://www.streetsafe.supply/results

This wonderful organization is a public service of UNC Chapel Hill and offers testing of street drugs. They serve drug users unions, harm reduction organizations, clinics, and health departments. Law enforcement is NOT allowed to use their services. The tests are free to some non-profit organizations but agencies or individuals who send in larger volumes of samples for testing may be charged a fee.

This is high-quality testing, using GC/MS (gas chromatography/mass spectrophotometry). One of their goals is to inform people about what is in the drug supply now. Samples sent to this organization are assigned a code, and the person sending the sample can go to the website, input their code, and results of their sample are on the website.

So much data in the field of addiction medicine takes time to collect and analyze, so it’s valuable to have data available so quickly.

I invite readers to go to UNC’s Street Safe website and click on the sample analyses sent in anonymously, to get an idea of what’s presently being sold on the streets.

I communicated with Dr. Nabarun Dasgupta, UNC Street Safe’s senior scientist, and asked how many drug samples he’s found that contain medetomidine. He said he’s found it in only a handful of samples.  It was first detected in October of 2022, in a sample that also contained fentanyl, methamphetamine, and xylazine. He has a grant to continue monitoring for medetomidine and other new drugs in the future.

The bottom line for our patients and for people using drugs is that what’s being sold as fentanyl may also contain sedatives like the alpha-2-adrenergic agonists xylazine or medetomidine, and possibly some other stuff like methamphetamines. The drugs may be more sedating than expected, which emphasizes the importance of NOT using alone and having Narcan available. Though Narcan won’t reverse medetomidine, it will reverse fentanyl or other opioids.

This class of drugs, the alpha-2-adrenergic agonists, may cause bigger problems in the future. I plan to stay tuned to scientists like Dr. Dasgupta to get accurate and up to date information.

Create your own website, free on WordPress.com.Create your own website.
Start free